Samuel Evans, MD
Critical Care Medicine · North Attleboro, MANPI 1508029356
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,827 of the $2,050 with a category attached, or 89.1%. 28 manufacturers reported payments, led by AstraZeneca at 26.2% of the total.
Across 84 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$537
- Olympus Corporation Of The Americas$263
- GSK$215
- Boehringer Ingelheim$140
- Daiichi Sankyo Inc.$104
- Novo Nordisk$71
- plus $719 from 22 others
What the payments were for
- Travel & lodging$20810%
- Food & beverage$1,82789%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $537 |
| Olympus Corporation Of The Americas | 2 | $263 |
| GSK | 9 | $215 |
| Boehringer Ingelheim | 6 | $140 |
| Daiichi Sankyo Inc. | 4 | $104 |
| Novo Nordisk | 4 | $71 |
| Harmony Biosciences LLC | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Pfizer | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 2 | $57 |
| Sanofi | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $46 |
| Exact Sciences | 2 | $40 |
| Grifols USA, LLC | 2 | $39 |
| Amgen | 2 | $26 |
| AbbVie | 1 | $25 |
| Dexcom, Inc. | 1 | $23 |
| Medtronic | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Bayer | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,050 in reported general payments places this provider in the 80th percentile of 158 critical care medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $155,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $64,622 |
| Spiriva RespimatTiotropium Bromide | 37 | $24,421 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $23,280 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $20,802 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $18,071 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $15,563 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $13,475 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $12,606 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $8,263 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 230 | $5,937 |
| Arnuity ElliptaFluticasone Furoate | 12 | $5,768 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,733 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,567 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $140 | $210,726100 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $215 | $122,708179 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $537 | $29,06553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 158 critical care medicine providers in Massachusetts.
Other critical care medicine in North Attleboro
- Richard ChannickBoston$638K
- Ioana PrestonBurlington$544K
- Mark TidswellSpringfield$135K
- Benjamin MedoffBoston$98K
- Jerome CrowleyBoston$38K
- William McGeeSpringfield$32K
- Diana Espinoza BarreraBoston$17K
- Raghu SeethalaWeymouth$14K
- Catherine FioreBoston$13K
- Ilana KrummBoston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.